Literature DB >> 34504026

Clinical Correlation of Multiple Sclerosis Immunopathologic Subtypes.

W Oliver Tobin1, Alicja Kalinowska-Lyszczarz1, Stephen D Weigand1, Yong Guo1, Nirubol Tosakulwong1, Joseph E Parisi1, Imke Metz1, Josa M Frischer1, Hans Lassmann1, Wolfgang Brück1, Linda Linbo1, Claudia F Lucchinetti2.   

Abstract

BACKGROUND AND OBJECTIVES: The goal of this work was to compare clinical characteristics across immunopathologic subtypes of patients with multiple sclerosis.
METHODS: Immunopathologic subtyping was performed on specimens from 547 patients with biopsy- or autopsy-confirmed CNS demyelination.
RESULTS: The frequency of immunopathologic subtypes was 23% for pattern I, 56% for pattern II, and 22% for pattern III. Immunopatterns were similar in terms of age at autopsy/biopsy (median age 41 years, range 4-83 years, p = 0.16) and proportion female (54%, p = 0.71). Median follow-up after symptom onset was 2.3 years (range 0-38 years). In addition to being overrepresented among autopsy cases (45% vs 19% in biopsy cohort, p < 0.001), index attack-related disability was higher in pattern III vs II (median Expanded Disability Status Scale score 4 vs 3, p = 0.02). Monophasic clinical course was more common in patients with pattern III than pattern I or II (59% vs 33% vs 32%, p < 0.001). Similarly, patients with pattern III pathology were likely to have progressive disease compared to patients with patterns I or II when followed up for ≥5 years (24% overall, p = 0.49), with no differences in long-term survival, despite a more fulminant attack presentation.
CONCLUSION: All 3 immunopatterns can be detected in active lesions, although they are found less frequently later into the disease due to the lower number of active lesions. Pattern III is associated with a more fulminant initial attack than either pattern I or II. Biopsied patients appear to have similar long-term outcomes regardless of their immunopatterns. Progressive disease is less associated with the initial immunopattern and suggests convergence into a final common pathway related to the chronically denuded axon.
© 2021 American Academy of Neurology.

Entities:  

Mesh:

Year:  2021        PMID: 34504026      PMCID: PMC8601208          DOI: 10.1212/WNL.0000000000012782

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  24 in total

1.  Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion.

Authors:  Michael H Barnett; John W Prineas
Journal:  Ann Neurol       Date:  2004-04       Impact factor: 10.422

2.  Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination.

Authors:  C Lucchinetti; W Brück; J Parisi; B Scheithauer; M Rodriguez; H Lassmann
Journal:  Ann Neurol       Date:  2000-06       Impact factor: 10.422

3.  The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability.

Authors:  B G Weinshenker; B Bass; G P Rice; J Noseworthy; W Carriere; J Baskerville; G C Ebers
Journal:  Brain       Date:  1989-02       Impact factor: 13.501

4.  Cataractogenicity and bioactivation of naphthalene derivatives in lens culture and in vivo.

Authors:  B M Lubek; S Kubow; P K Basu; P G Wells
Journal:  Lens Eye Toxic Res       Date:  1989

5.  Mitochondrial dysfunction plays a key role in progressive axonal loss in Multiple Sclerosis.

Authors:  H E Andrews; P P Nichols; D Bates; D M Turnbull
Journal:  Med Hypotheses       Date:  2005       Impact factor: 1.538

6.  Differentiation between cellular apoptosis and necrosis by the combined use of in situ tailing and nick translation techniques.

Authors:  R Gold; M Schmied; G Giegerich; H Breitschopf; H P Hartung; K V Toyka; H Lassmann
Journal:  Lab Invest       Date:  1994-08       Impact factor: 5.662

7.  Diffusion-weighted imaging characteristics of biopsy-proven demyelinating brain lesions.

Authors:  N Abou Zeid; I Pirko; B Erickson; S D Weigand; K M Thomsen; B Scheithauer; J E Parisi; C Giannini; L Linbo; C F Lucchinetti
Journal:  Neurology       Date:  2012-05-09       Impact factor: 9.910

Review 8.  Pathological mechanisms in progressive multiple sclerosis.

Authors:  Don H Mahad; Bruce D Trapp; Hans Lassmann
Journal:  Lancet Neurol       Date:  2015-02       Impact factor: 44.182

9.  International consensus diagnostic criteria for neuromyelitis optica spectrum disorders.

Authors:  Dean M Wingerchuk; Brenda Banwell; Jeffrey L Bennett; Philippe Cabre; William Carroll; Tanuja Chitnis; Jérôme de Seze; Kazuo Fujihara; Benjamin Greenberg; Anu Jacob; Sven Jarius; Marco Lana-Peixoto; Michael Levy; Jack H Simon; Silvia Tenembaum; Anthony L Traboulsee; Patrick Waters; Kay E Wellik; Brian G Weinshenker
Journal:  Neurology       Date:  2015-06-19       Impact factor: 9.910

10.  Iron Heterogeneity in Early Active Multiple Sclerosis Lesions.

Authors:  Mylyne Tham; Josa M Frischer; Stephen D Weigand; Patrick D Fitz-Gibbon; Samuel M Webb; Yong Guo; Reginald C Adiele; Christopher A Robinson; Wolfgang Brück; Hans Lassmann; Kendra L Furber; M Jake Pushie; Joseph E Parisi; Claudia F Lucchinetti; Bogdan F Popescu
Journal:  Ann Neurol       Date:  2020-12-19       Impact factor: 10.422

View more
  7 in total

1.  Population-based incidence and clinico-radiological characteristics of tumefactive demyelination in Olmsted County, Minnesota, United States.

Authors:  Mahboubeh Fereidan-Esfahani; Paul A Decker; Jeanette E Eckel Passow; Claudia F Lucchinetti; Eoin Patrick Flanagan; William Oliver Tobin
Journal:  Eur J Neurol       Date:  2021-12-09       Impact factor: 6.089

Review 2.  Pathogenic autoantibodies in multiple sclerosis - from a simple idea to a complex concept.

Authors:  Romana Höftberger; Hans Lassmann; Thomas Berger; Markus Reindl
Journal:  Nat Rev Neurol       Date:  2022-08-15       Impact factor: 44.711

3.  The Potential for EBV Vaccines to Prevent Multiple Sclerosis.

Authors:  Peter A Maple; Alberto Ascherio; Jeffrey I Cohen; Gary Cutter; Gavin Giovannoni; Claire Shannon-Lowe; Radu Tanasescu; Bruno Gran
Journal:  Front Neurol       Date:  2022-06-24       Impact factor: 4.086

Review 4.  Ponesimod in the Treatment of Relapsing Forms of Multiple Sclerosis: An Update on the Emerging Clinical Data.

Authors:  Serena Ruggieri; Maria Esmeralda Quartuccio; Luca Prosperini
Journal:  Degener Neurol Neuromuscul Dis       Date:  2022-03-22

Review 5.  Tissue donations for multiple sclerosis research: current state and suggestions for improvement.

Authors:  Patrick Vanderdonckt; Francesca Aloisi; Giancarlo Comi; Alexander de Bruyn; Hans-Peter Hartung; Inge Huitinga; Tanja Kuhlmann; Claudia F Lucchinetti; Imke Metz; Richard Reynolds; Hans Lassmann
Journal:  Brain Commun       Date:  2022-04-19

Review 6.  Motor Behavioral Deficits in the Cuprizone Model: Validity of the Rotarod Test Paradigm.

Authors:  Concordia Lubrich; Paula Giesler; Markus Kipp
Journal:  Int J Mol Sci       Date:  2022-09-26       Impact factor: 6.208

Review 7.  The contribution of neuropathology to multiple sclerosis research.

Authors:  Hans Lassmann
Journal:  Eur J Neurol       Date:  2022-06-23       Impact factor: 6.288

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.